Ocular Therapeutix: Dextenza Sales Accelerating, Near-Term C

Ocular Therapeutix' shares have lost a quarter of their value so far this year. Check out why I rate OCUL stock as a buy.

Related Keywords

Australia , Japan , Rabia Ozden , Anthony Mattessich , Jonathan Knowles , Michael Goldstein , Kodiak Sciences , Twitter , Ocular Therapeutix , Corporate Slides , Opaleye Management , Summer Road , Board Michael Warden , Chief Medical Officer Rabia Ozden , Nightstar Therapeutics , Compensation Table , Executive Compensation Table , Proxy Filing , Sentiv Capital , Core Biotech ,